CEL-SCI Corporation, a clinical stage cancer immunotherapy company, announced a public offering of its common stock and/or pre-funded warrants. The offering is being conducted on a best-efforts basis, with ThinkEquity acting as the sole placement agent. The proceeds from this offering will be used to advance the development of CEL-SCI's Multikine, as well as for general corporate purposes and working capital. The company has filed a shelf registration statement with the U.S. Securities and Exchange Commission, and the offering will be made via a written prospectus. Investors are encouraged to review the prospectus for detailed information about the offering and the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250827778416) on August 27, 2025, and is solely responsible for the information contained therein.